Implant-Associated P. Aeruginosa Bone And Joint Infections : Experience In A Regional Reference Center In France

Completed

• Conditions: Bone and Joint Infection
• Interventions: Other: Bone or joint infection due to Pseudomonas aeruginosa

• Registration Number: NCT03624855
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

The aim of this study is to describe the bone or joint infection due to Pseudomonas aeruginosa in patients having implant.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-03-01
• Primary Completion: 2018-05-01
• Study Completion: 2018-05-01
• Status Verified: 2018-08
• Study First Submitted: 2018-08-06
• Study First Submitted QC: 2018-08-06
• Study First Posted: 2018-08-10
• Last Update Submitted: 2018-08-10
• Last Update Posted: 2018-08-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 94

Inclusion Criteria

• patients having BJI on implant caused by Pseudomonas aeruginosa

Read More

Exclusion Criteria

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Description of BJI due to Pseudomonas aeruginosa	Bone or joint infection due to Pseudomonas aeruginosa	patients having bone and joint infection on implant due to Pseudomonas aeruginosa

Primary Outcome Measures

Name	Time	Method
Description and rate of bone or joint infection on implant caused due to Pseudomonas aeruginosa	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)	Description of the type of infection due to P. aeruginosa : patients and type of implant, profile of the bacterium, medical and chirurgical treatment, rate

Secondary Outcome Measures

Name	Time	Method
Rate of adverse events occurring under medical treatment against Pseudomonas aeruginosa	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)	description of adverse events occurring under medical treatment against Pseudomonas aeruginosa in BJI
Rate of Treatment Failure	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)	Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin

Trial Locations

Locations (1)

Hospices Civils de Lyon; 🇫🇷 Lyon, France